Clinical trials: ST-elevation Myocardial Infarction (STEMI)
Myocardial Infarction
Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce the damage to the muscle that occurs with a heart attack.
- Trial name
- NCT00093197
- Testing
- KAI-9803 for Injection
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- KAI Pharmaceuticals
Acute ST-segment Elevation Myocardial Infarction
EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction
The EARLY-MYO (EARLY routine catheterization after alteplase fibrinolysis vs. primary PCI in acute ST-segment elevation MYOcardial infarction) is an investigator-initiated, prospective, multicenter, randomized (1:1), open-label…
- Trial name
- EARLY-MYO (NCT01930682)
- Testing
- Alteplase, Early post-fibrinolytic catheterisation, Primary PCI
- Where
- China
- Volunteers
- 344 people
- Sponsor
- RenJi Hospital
STEMI, Chest Pain
Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial
The investigators propose to test the effectiveness of a technique that uses a modified commercially available ultrasound system used for cardiac imaging, and a commercially available ultrasound contrast agent (microbubbles) to…
- Trial name
- MRUSMI (NCT02170103)
- Testing
- percutaneous intervention (PCI), Microbubbles, Ultrasound
- Where
- 2 sites in Brazil, Netherlands
- Volunteers
- 50 people
- Sponsor
- University of Nebraska
Nicorandil
Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention
To study the effects of early oral administration of nicorandil in the setting of PPCI among STEMI patients on early angiographic, electrocardiographic, echocardiographic and hard clinical outcomes.
- Trial name
- NCT04632121
- Testing
- Nicorandil 20 MG
- Volunteers
- 300 people
- Sponsor
- Ahmed Abdel Nasser Abdel Rady
Safety Issues
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment…
- Trial name
- NCT05724576
- Testing
- OmniMSC-AMI
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Taiwan Bio Therapeutics Inc.
Myocardial Infarction, No Reflow Phenomenon
Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI.
- Trial name
- VaBiNoR (NCT07132489)
- Testing
- HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
- Volunteers
- 114 people
- Sponsor
- Assiut University
Acute Coronary Syndrome
FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes
The objective of this study is to evaluate the safety and efficacy of A 002 when added to high dose atorvastatin in subjects with an acute coronary syndrome (ACS)
- Trial name
- FRANCIS-ACS (NCT00743925)
- Testing
- Varespladib Methyl (A-002)
- Where
- 44 sites in Georgia, Russia and 1 more
- Volunteers
- 625 people
- Sponsor
- Anthera Pharmaceuticals
STEMI
ReModeling in ST-elevation myocARrdial Infarction: a Comparison of Left VEntricuLar Functions in Long-term Follow-up Among STEMI Patients
Patients diagnosed with STEMI who underwent pPCI were included in this study. The investigators collected comprehensive data on each patient's status, including laboratory findings such as NT-proBNP, troponin levels, and…
- Trial name
- MARVEL (NCT07041840)
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- University of Pisa
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI)
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
The study aims to determine the feasibility and clinical utility of incorporating precision medicine approaches, incorporating both cytochrome P450 2C19 (CYP2C19) genotyping and platelet reactivity phenotyping, with standard of…
- Conditions
- Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
- Trial name
- NCT04090281
- Testing
- CYP2C19 genotyping
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Southern California
Acute Myocardial Infarction, STEMI
Evaluation in STEMI Patients Using FDY-5301
To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
- Conditions
- Acute Myocardial Infarction, STEMI, Percutaneous Coronary Revascularization
- Trial name
- IOCYTE AMI-3 (NCT04837001)
- Testing
- FDY-5301
- Where
- 52 sites in United States, Canada and 4 more
- Volunteers
- 2,351 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Non-ST-segment Elevation Myocardial Infarction, Chronic Kidney Disease
Optimised Procedure in Patients With NSTEMI and CKD
Aim of the study is the determination of the ideal timepoint for the treatment of patients with acute Non-ST-segment Elevation Myocardial Infarction (NSTEMI) and an acute or chronic kidney disease (CKD) with a GRACE score < 140.
- Trial name
- NSTEMI-CKD (NCT02543177)
- Testing
- coronary angiography, ischemic precondition, prior kidney irrigation
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- RWTH Aachen University
Myocardial Infarction
Postconditioning in ST-elevation Myocardial Infarction
Study objectives: To assess the effects of postconditioning on infarct size in patients with ST-elevation infarction referred to PCI. Study design: Prospective, randomized, open-label study with blinded endpoint evaluation.
- Trial name
- POSTEMI (NCT00922675)
- Testing
- Postconditioning, Control intervention
- Where
- Norway
- Volunteers
- 272 people
- Sponsor
- Oslo University Hospital
Myocardial Infarction, Acute, ST Segment Elevation Myocardial Infarction
A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction
The purpose of this pilot study is to evaluate the effectiveness of the active involvement of Community Pharmacists in improving adherence to medical prescriptions in patients with acute myocardial infarction (AMI), reducing the…
- Conditions
- Myocardial Infarction, Acute, ST Segment Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction (nSTEMI)
- Trial name
- IM-ADHERENCE (NCT03621111)
- Testing
- Patient-counseling, Patient self-administered questionnaire, Pills counts
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Azienda ULSS 5 Polesana
Cto, Acef Score
Prognostic Value of The Age, Creatinine, and Ejection Fraction Score for Non-infarct-related Chronic Total Occlusion Revascularization After Primary Percutaneous Intervention in Acute ST-elevation Myocardial Infarction Patients: A Retrospective Study
The age, creatinine, and ejection fraction (ACEF) score has been used to evaluate the clinical prognostic to patients who underwent PCI.
- Trial name
- NCT02833636
- Testing
- ACEF score
- Volunteers
- 2,952 people
- Sponsor
- Xibei Hospital
Ischemic Heart Disease, Stable Coronary Artery Disease
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)
- Conditions
- Ischemic Heart Disease, Stable Coronary Artery Disease, Stable Angina, Unstable Angina
- Trial name
- NCT03089450
- Testing
- CGBio stent, Biomatrix flex
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- CGBio Inc.
Acute ST Elevation Myocardial Infarction
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial.
- Trial name
- HEAT-PPCI (NCT01519518)
- Testing
- unfractionated heparin, Bivalirudin
- Where
- United Kingdom
- Volunteers
- 1,829 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Acute ST Segment Elevation Myocardial Infarction
Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct
Patients presenting with acute ST elevation myocardial infarct urgently need revascularization. Standard of care is establishing bloodflow through the coronary vessels using thrombus aspiration catheter, and securing the result…
- Trial name
- BVS in STEMI (NCT02067091)
- Testing
- stent implant in a coronary artery
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 120 people
- Sponsor
- Haukeland University Hospital
Myocardial Reperfusion Injury
Delayed Postconditioning
The investigators previously reported that angioplasty postconditioning reduces infarct size (cardiac enzyme release) in STEMI patients with a fully occluded coronary artery at hospital admission.
- Trial name
- PRIME (NCT01483755)
- Testing
- Postconditioning, Percutaneaous intervention
- Where
- 5 sites in France
- Volunteers
- 72 people
- Sponsor
- Hospices Civils de Lyon
ST-elevation Myocardial Infarction
Cost-effectiveness of Remote Ischemic Conditioning as an Adjunct to Primary Percutaneous Coronary Intervention
The aim of this study is to investigate the cost-effectiveness of remote ischemic conditioning as an adjunct to primary percutaneous coronary intervention from the perspective of a Danish healthcare system.
- Trial name
- NCT02431338
- Testing
- Remote ischemic conditioning
- Where
- Denmark
- Volunteers
- 333 people
- Sponsor
- University of Aarhus
Non ST-elevation Myocardial Infarction
Brilinta Taiwan Post Approval Safety Study
A multicenter, single arm, open label, Phase IV study to evaluate safety and to describe the cumulative incidence of major cardiovascular events of Ticagrelor in Taiwanese patients with non ST-segment (a segment in the…
- Trial name
- NCT02406248
- Testing
- Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
- Where
- 13 sites in Taiwan
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.